ArticleNucleic acids research2017
GenomeCRISPR - a database for high-throughput CRISPR/Cas9 screens.
Article in Nucleic acids research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 84 citations in OpenAlex.
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Review
- GEMap: A comprehensive gene essentiality map for drug discovery.Acta pharmaceutica Sinica. B · 2026Article
- Advancing CRISPR with deep learning: A comprehensive review of models and databases.Molecular therapy. Nucleic acids · 2025Review
- In silico biological discovery with large perturbation models.Nature computational science · 2025Article
- Unlocking the potential of CRISPR tools and databases for precision genome editing.Frontiers in plant science · 2025Review
- Emerging RNAi Therapies to Treat Hypertension.Molecular diagnosis & therapy · 2025Review
- The Evolution of Nucleic Acid-Based Diagnosis Methods from the (pre-)CRISPR to CRISPR era and the Associated Machine/Deep Learning Approaches in Relevant RNA Design.Methods in molecular biology (Clifton, N.J.) · 2025Article
- A scalable platform for efficient CRISPR-Cas9 chemical-genetic screens of DNA damage-inducing compounds.Scientific reports · 2024Article
- Programming human cell fate: overcoming challenges and unlocking potential through technological breakthroughs.Development (Cambridge, England) · 2023Article
- 3Bs of CRISPR-Cas mediated genome editing in plants: exploring the basics, bioinformatics and biosafety landscape.Physiology and molecular biology of plants : an international journal of functional plant biology · 2023Review
- Optimized minimal genome-wide human sgRNA library.Scientific reports · 2023Article
- Using traditional machine learning and deep learning methods for on- and off-target prediction in CRISPR/Cas9: a review.Briefings in bioinformatics · 2023Review
- Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions.Frontiers in bioengineering and biotechnology · 2023Review
- Review
- EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.Cell death & disease · 2022Article
- Review
- Integrated cross-study datasets of genetic dependencies in cancer.Nature communications · 2021Article
- Domain-specific introduction to machine learning terminology, pitfalls and opportunities in CRISPR-based gene editing.Briefings in bioinformatics · 2021Review
- Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets.Nucleic acids research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past years, CRISPR/Cas9 mediated genome editing has developed into a powerful tool for modifying genomes in various organisms. In high-throughput screens, CRISPR/Cas9 mediated gene perturbations can be used for the systematic functional analysis of whole genomes. Discoveries from such screens provide a wealth of knowledge about gene to phenotype relationships in various biological model systems. However, a database resource to query results efficiently has been lacking. To this end, we developed GenomeCRISPR (http://genomecrispr.org), a database for genome-scale CRISPR/Cas9 screens. Currently, GenomeCRISPR contains data on more than 550 000 single guide RNAs (sgRNA) derived from 84 different experiments performed in 48 different human cell lines, comprising all screens in human cells using CRISPR/Cas published to date. GenomeCRISPR provides data mining options and tools, such as gene or genomic region search. Phenotypic and genome track views allow users to investigate and compare the results of different screens, or the impact of different sgRNAs on the gene of interest. An Application Programming Interface (API) allows for automated data access and batch download. As more screening data will become available, we also aim at extending the database to include functional genomic data from other organisms and enable cross-species comparisons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.